Skip to main content

Table 4 Clinical characteristics and their prediction of overall survival in 127 HCC patients

From: Polymorphism in asparagine synthetase is associated with overall survival of hepatocellular carcinoma patients

Characteristics

Number

Survival Time, m mean (95%CI)

P

OR (95%CI)

Gender

  

0.68

1.12(0.65–1.93)

 male

107

39.1(35.1–43.2)

  

 female

20

41.8(31.0–52.6)

  

Smoking

  

0.24

0.72(0.41–1.25)

 No

86

40.8(36.1–45.4)

  

 Yes

41

37.0(30.7–43.4)

  

Drinking

  

0.90

1.04(0.57–1.89)

 No

97

40.3(36.0–44.6)

  

 Yes

30

37.1(29.3–45.0)

  

Family history of HCC

  

0.16

0.65(0.36–1.19)

 No

114

40.6(36.7–44.6)

  

 Yes

13

30.2(18.0–42.4)

  

rs1049674

  

0.829

0.80(0.10–6.17)

 TT

1

54.2

  

 TA

22

33.6(24.0–43.2)

  

 AA

104

40.7(36.6–44.8)

  

rs34050735

  

0.001

7.21(2.30–22.6)

 TT

4

15.2(−2.4–32.7)

  

 TG

35

34.4(27.7–41.1)

  

 GG

88

42.7(38.2–47.2)

  

Vascular invasion

  

0.51

0.86(0.55–1.34)

 No

78

39.2(34.4–44.1)

  

 Yes

49

40.1(34.1–46.0)

  

Differentiation

  

0.28

1.27(0.82–1.97)

 I + II

65

38.9(33.4–44.4)

  

 III + IV

62

40.3(35.1–45.4)

  

TNM stage

  

0.53

0.88(0.60–1.30)

 I + II

75

39.6(34.8–44.5)

  

 III + IV

52

39.4(33.4–45.5)